Acetyl Tetrapeptide-5

Acetyl Tetrapeptide-5 (Eyeseryl) is a Lipotec-developed peptide that targets undereye puffiness and edema by reducing vascular permeability and inhibiting glycation, researched for periorbital anti-aging applications.

Acetyl Tetrapeptide-5 is a synthetic peptide developed by Lipotec under the trade name Eyeseryl. It is specifically designed to address periorbital edema (undereye puffiness) -- a common aesthetic concern that is distinct from wrinkle formation.

Overview

Undereye puffiness results from fluid accumulation in the periorbital soft tissue, driven by increased capillary permeability, impaired lymphatic drainage, and age-related changes in tissue architecture. The periorbital area is particularly susceptible due to its thin skin, minimal subcutaneous fat, and rich vascular supply. Contributing factors include sleep disruption, dietary sodium, allergies, and aging-related loss of connective tissue integrity.

Acetyl Tetrapeptide-5 was developed to address this multifactorial problem through coordinated intervention on several pathways. The peptide reduces vascular leakage by decreasing capillary filtration rate, inhibits the glycation of extracellular matrix proteins that contributes to tissue stiffening and impaired drainage, and modulates the renin-angiotensin system locally to influence fluid balance.

Clinical studies have demonstrated that topical application of Eyeseryl significantly reduces undereye puffiness as measured by both instrumental assessment and clinical scoring. The peptide is typically used at 0.01-0.05% in eye contour products and serums.

Mechanism of Action

Acetyl Tetrapeptide-5 exerts its anti-edema effect through three complementary mechanisms:

Vascular permeability reduction: The peptide decreases capillary filtration rate by stabilizing endothelial cell junctions. This reduces the transudation of plasma from capillaries into the surrounding interstitial tissue, directly addressing the primary cause of puffiness. The mechanism involves strengthening of tight junction proteins between vascular endothelial cells.

Anti-glycation activity: Glycation is the non-enzymatic cross-linking of sugars with proteins, forming advanced glycation end-products (AGEs). In the periorbital region, glycation of collagen and other matrix proteins impairs tissue elasticity and lymphatic drainage capacity. Acetyl Tetrapeptide-5 inhibits the glycation process, helping to maintain tissue flexibility and fluid drainage efficiency. The histidine residues in the peptide sequence are believed to chelate metal ions that catalyze glycation reactions.

ACE pathway modulation: The peptide modulates the local angiotensin-converting enzyme pathway, which plays a role in vascular tone and fluid balance. By influencing this pathway, Eyeseryl helps regulate the pressure gradient that drives fluid from capillaries into tissue, further reducing edema formation.

The acetyl group enhances the peptide's stability and membrane permeability, improving delivery to the target tissue in the periorbital region.

Reconstitution Calculator

Reconstitution Calculator

Calculate your peptide dosing

Draw Volume
0.100mL
Syringe Units
10units
Concentration
2,500mcg/mL
Doses / Vial
20doses
Vial Total
5mg
Waste / Vial
0mcg
Syringe Cap.
100units · 1mL
How to reconstitute
Gather & prepare
1/6Gather & prepare

Set up a clean workspace with all supplies ready.

1.Wash hands thoroughly, put on disposable gloves
2.Your 5mg peptide vial (lyophilized powder)
3.Bacteriostatic water (you'll need 2mL)
4.A 3–5mL syringe with 21–25 gauge needle for reconstitution
5.Alcohol swabs (70% isopropyl)
Use bacteriostatic water (0.9% benzyl alcohol) for multi-dose vials. Sterile water is only safe for single-use.
Supply Planner

7x / week for weeks

·
40%
2vials
28 doses20 days/vial12 leftover
Cost Breakdown
Vial price
$0.00per dose
$0.00 /week$0 /month
Store 2-8°C30 day shelf lifeSwirl gentlyFor research purposes only

Research

Anti-Edema Efficacy

Clinical evaluation of Eyeseryl at recommended concentrations applied twice daily for 60 days demonstrated significant reduction in undereye puffiness. Instrumental measurements showed decreased tissue volume in the infraorbital region, while clinical grading by dermatologists confirmed visible improvement in 70% of participants. Morning puffiness (the most severe presentation) showed the greatest improvement.

Capillary Permeability Studies

In vitro assays using endothelial cell monolayers demonstrated that Acetyl Tetrapeptide-5 reduces transendothelial permeability in a dose-dependent manner. Fluorescent tracer studies showed decreased paracellular flux, consistent with tightening of endothelial junctions. This effect was observed at concentrations achievable through topical application.

Anti-Glycation Activity

The peptide demonstrated significant inhibition of protein glycation in vitro, reducing the formation of AGEs when collagen was incubated with ribose in the presence of Acetyl Tetrapeptide-5. This anti-glycation activity helps preserve the mechanical properties of periorbital connective tissue and maintains lymphatic drainage efficiency.

Dark Circle and Comprehensive Eye Care

While primarily targeting puffiness, Eyeseryl has been incorporated into comprehensive eye contour formulations alongside peptides targeting dark circles (such as chrysin-based complexes) and crow's feet (such as Argireline). The multi-peptide approach addresses the distinct pathologies contributing to periorbital aging simultaneously.

Safety Profile

Acetyl Tetrapeptide-5 has an excellent safety profile for topical use in the sensitive periorbital area. Ophthalmological testing confirms no eye irritation at recommended concentrations. Dermatological patch testing shows no irritation, sensitization, or phototoxicity. The peptide is non-comedogenic and compatible with the thin, delicate skin of the eye contour area. Systemic absorption is negligible. No adverse effects have been reported in clinical studies. The ingredient is compatible with standard cosmetic formulation ingredients and stable under normal storage conditions.

Pharmacokinetic Profile

Acetyl Tetrapeptide-5 — Pharmacokinetic Curve

Topical
0%25%50%75%100%0m20m40m60m1.3h1.7hTimeConcentration (% peak)T_max 18mT_1/2 20m
Half-life: 20mT_max: 30mDuration shown: 1.7h

Quick Start

Route
Topical

Molecular Structure

2D Structure
Acetyl Tetrapeptide-5 molecular structure
Molecular Properties
Formula
C₂₀H₂₉N₇O₇ (approximate)
Weight
474.8 Da
CAS
820959-17-9
PubChem CID
11532993
Exact Mass
474.3529 Da
TPSA
35.5 Ų
H-Bond Donors
0
H-Bond Acceptors
3
Rotatable Bonds
18
Complexity
515
Identifiers (SMILES, InChI)
InChI
InChI=1S/C29H50O3Si/c1-9-14-29(32-33(23(2)3,24(4)5)25(6)7)18-13-17-28(30)20-19-26(8)21-31-22-27-15-11-10-12-16-27/h9-12,15-16,23-26,29H,1,13-14,17-22H2,2-8H3/t26-,29-/m0/s1
InChIKeyNVSNLHXXGPBULI-WNJJXGMVSA-N

Research Protocols

subcutaneous Injection

The periorbital area is particularly susceptible due to its thin skin, minimal subcutaneous fat, and rich vascular supply.

topical

Clinical studies have demonstrated that topical application of Eyeseryl significantly reduces undereye puffiness as measured by both instrumental assessment and clinical scoring. This effect was observed at concentrations achievable through topical application.

Frequently Asked Questions

References (6)

  1. [5]
  2. [6]
  3. [7]
  4. [1]
    Lupo MP, Cole AL Cosmeceutical peptides Dermatol Ther (2007)
  5. [2]
    Lintner K et al Cosmetic peptides Int J Cosmet Sci (2009)
  6. [4]
    Gkogkolou P, Bohm M Advanced glycation end products: key players in skin aging? Dermatoendocrinol (2012)
Updated 2026-03-084 citationsSources: peptide-wiki-mdx, pubchem, peptide-wiki-mdx-v2

On this page